Daily Peptide Briefing

LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial.

BMJ open

Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis.

Clinical kidney journal

Differential Effects of Semaglutide and Colchicine on Atrial Remodeling in Rats with Reduced Ejection Fraction after Myocardial Infarction.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study.

npj aging

The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review.

Molecular and cellular neurosciences

Cost-Effectiveness of Incretin Therapies: A Canadian Lens on Diabetes, Obesity, and Emerging Indications.

Canadian journal of physiology and pharmacology

Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.

Journal of medical economics

Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs).

Diabetes therapy : research, treatment and education of diabetes and related disorders

BEST PEPTIDES: S-Tier: Tirzepatide, Tesamorelin, Oxytocin A-Tier: Semaglutide, Sermorelin, Melanotan 1 B-Tier: NAD+ C-Tier: Everything else due to purity issues, until they can be legally compounded by US pharmacies (e.g. Retatrutide, BPC-157, TB-4, CJC, MT2, MOTS-c, etc.)

SKIP HYPE: If you want to HEAL faster, Skip BPC-157 (poor data) Take a Growth Hormone peptide (TESAMORELIN) If you want to lose FAT, Skip Reta (stimulates the heart) Take a GLP-1/GIP (TIRZEPATIDE) If you want to feel CALM, Skip Selank (poor data) Take a neuropeptide (OXYTOCIN)

@TheLongInvest For now, it's $HIMS. But I suspect it'll be $AVCT #AVCT in the not-too-distant future. The large majority of US retail associate #peptides with the GLP-1 mimetics (semaglutide, tirzepatide) and bioregulatory / research peptides (e.g. BPC-157; TB-500; GHK-Cu, etc.). But the

Amazon just launched a GLP-1 program through One Medical. $149/mo oral. $299/mo injectable. But GLP-1s are one peptide class out of dozens. BPC-157, Thymosin Beta-4, GHK-Cu, MOTS-c... the real wave hasn't even started. The FDA is deregulating 12+ peptides. Amazon is entering https://t.co/NqBTc9WhHt

🚨 $HIMS +46% in 1 week as FDA schedules peptide compounding review (July 23–24) The FDA will evaluate 7 peptides for compounding eligibility: → BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon ✅Hims & Hers CMO called it an “avenue toward trusted channels” This is https://t.co/yKIFM6lEZh

This week the FDA quietly admitted the research peptide community was right ALL ALONG!!!!! For 3 years they called BPC-157 "high-risk" and blocked access. No evidence. No bodies. Just bureaucratic theater. Now they're walking it back. Here's what it actually means 🧵

BREAKING NEWS: Peptides are coming In July, the FDA is reviewing BPC-157, TB-500, Semax, Epitalon and more. The meeting will be open to the public. The peptide era begins. https://t.co/hGR3ZPfhnU

Did a bit of research and seems like these are most used peptides: -tirzepatide -semaglutide -BPC-157 -TB-500 -ipamorelin What do you think of peptides?